Shippeo’s Shipment Tracking ETA Accuracy Leaps Forward With a Giant 32% Improvement
26.4.2022 13:27:00 EEST | Business Wire | Press release
Shippeo, a leading provider of global shipment visibility, has achieved a significant advancement in its predictive shipment ETA performance, aided by investments in new AI/ML infrastructure and sophisticated algorithms. As a result, shippers and logistics service providers are seeing improved accuracy and reliability of estimated times of arrival (ETAs) of their shipments, thereby increasing the efficiency and predictability of their supply chains.
The recent challenges caused by major supply chain disruptions have reaffirmed the need for organisations to improve shipment traceability on a global scale. Although it has never been easier to track shipments travelling throughout the world in near real-time thanks to more affordable devices and better connectivity, the type of data that supply chain management values is changing.
Shippeo’s Chief Product Officer, Anand Medepalli, says: “The question supply chain managers are asking themselves is shifting from ‘where is my shipment’ at the macro level to a more granular ‘When will it arrive at the next stop?’ and ‘Are there any risks of a delay?’”. This means that the ability to predict shipment ETAs at a very granular level is increasingly becoming a must-have, critical capability for shippers.
This improved ETA brings a range of benefits to manufacturers. Shippeo customers report that having accurate ETA predictions for shipment arrival times improves team productivity at key delivery sites, while boosting KPI performance, increasing sales and, of course, raising customer satisfaction levels. At the same time, these manufacturers, many of which are operating globally, are decreasing stock-outs or production line halts by as much as 76%, as well as reducing late penalties by 25%, dwell times by 30% and reducing unexpected freight costs.
As with any algorithm, ETA accuracy depends heavily on the quality of data inputted, which is why Shippeo’s core R&D focus is to continually enhance the accuracy and reliability of the data feeding the ETA predictions. In its latest third release, in addition to data quality, the company has revamped its machine learning (ML) infrastructure, as well as the methodologies and models its data scientists and ML engineers use. The result is an impressive 32% improvement in ETA accuracy up to 48 hours before a scheduled delivery.
“This is really exciting for us given that several of our customers, including Renault Group, one of the world’s largest automotive manufacturers, have already told us that our ETA is impressive,” says Medepalli.
“Shippeo invests a lot in continually improving its ETA calculator algorithm, taking our feedback as users into account,” says Renan Filleur, Renault Group’s General Manager of Parts Logistic Operations and Performance. “ETA reliability results are an important focus and are made visible, which greatly supports Renault Group’s choice of Shippeo’s real-time visibility platform. This reliability is a critical element for any major industrial customer like Renault due to the genuine value it generates for the business.”
Shippeo is also the only real-time transportation visibility platform vendor offering contractual guarantees on its ETA accuracy, as well as carrier onboarding speed and high tracking rates. “The performance of our ETA model gives us the confidence to guarantee high accuracy for all of our customers or we give their money back,” explains Medepalli, “which means a guaranteed time to value for every customer. This relentless focus on customer satisfaction is what differentiates us from our competition.”
The enhanced ETA algorithm is available now for all Shippeo platform users.
- Ends -
About Shippeo (https://www.shippeo.com)
LinkedIn, Facebook, Twitter
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005484/en/
Contact information
Media
Europe: Andrea Krug, Krug Communications Ltd, Tel. +44 (0)7740 245 867, email: andrea@krugcomms.com
North America: Carol Kraeutler Lerner, CKL Communications, Tel. +1 (201) 602-7572, email: ckl.communications@gmail.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
